Literature DB >> 28608303

Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

Leonhard A Bakker1,2, Carin D Schröder2,3, Michael A van Es1, Paul Westers4, Johanna M A Visser-Meily2,3, Leonard H van den Berg5.   

Abstract

The amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) is a widely used primary outcome measure in amyotrophic lateral sclerosis (ALS) clinical practice and clinical trials. ALSFRS-R items cannot, however, validly be summed to obtain a total score, but constitute domain scores reflecting a profile of disease severity. Currently, there are different measurement models for estimating domain scores. The objective of the present study is, therefore, to derive the measurement model that best fits the data for a valid and uniform estimation of ALSFRS-R domain scores. Data from 1556 patients with ALS were obtained from a population-based register in The Netherlands. A random split of the sample provided a calibration and validation set. Measurement models of the ALSFRS-R were investigated using both exploratory factor analyses and confirmatory factor analyses. The measurement model with a four-factor structure (i.e., bulbar, fine motor, gross motor, and respiratory function), with correlated factors and cross-loading items on dressing and hygiene and turning in bed and adjusting bed clothes on both motor function scales, provided the best fit to the data in both sets. Correlation between factors ranged from weak to modest, confirming that the ALSFRS-R constitutes a profile of four clinically relevant domain scores rather than a total score that expresses disease severity. The internal consistency of the four domain scores was satisfactory. Our revision of the measurement model may allow for a more adequate estimation of disease severity and disease progression in epidemiological studies and clinical trials.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Amyotrophic lateral sclerosis functional rating scale-revised; Confirmatory factor analysis

Mesh:

Year:  2017        PMID: 28608303      PMCID: PMC5502060          DOI: 10.1007/s00415-017-8538-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor neurons for which there is currently no effective treatment. Disease progression in ALS is characterized by loss of physical function in various domains, i.e., the bulbar, fine and gross motor, and respiratory domain. The amyotrophic lateral sclerosis functional rating scale (ALSFRS) [1, 2] and its revised version (ALSFRS-R) [3] use this loss of function as a marker for disease severity and disease progression. To date, the ALSFRS-R is the most widely applied rating scale in clinical practice and clinical trials as primary or secondary outcome measure. Moreover, it has been translated into various languages [4-8] and adapted for administration to patients via internet [9], administration to patients and caregivers via telephone [10-12], and for self-administration [13]. The ALSFRS-R has demonstrated good criterion-related validity, and the inter-rater, intra-rater, and test–retest reliabilities of the ALSFRS-R are excellent [3, 7, 10, 14]. Recent studies have examined the factorial validity, i.e., the extent to which items measure the intended construct, of the ALSFRS-R using exploratory factor analyses [15], confirmatory factor analyses [15-17] and item response theory analyses [15-17], and have shown that its items do not constitute a total score, a general severity score, but rather a profile of domain scores [15-17]. Hence, the ALSFRS-R domain scores and a consistent strategy to estimate them are of special importance. In the literature, however, there appears to be a divide between those who use a measurement model with a four-factor structure (i.e., bulbar, fine and gross motor, and respiratory) [3, 4, 7, 17, 18], as hypothesized by the developers of the ALSFRS-R, and those who use an alternative measurement model with a three-factor structure, which combines fine and gross motor domains into one motor domain [5, 15, 16]. Consequently, there is currently not one distinct strategy for estimating ALSFRS-R domain scores. The application of various measurement models of the ALSFRS-R could give rise to inconsistent results in the literature. The primary objective of the present study is, therefore, to assess the factorial validity of the ALSFRS-R in a large sample of patients with ALS, to derive a measurement model that describes the data best for a valid and uniform estimation of ALSFRS-R domain scores. Furthermore, the internal consistency of these domain scores will be assessed.

Methods

Sample

ALSFRS-R data of patients who fulfilled the diagnostic criteria for possible, probable laboratory-supported, probable, and definite ALS, according to the revised El Escorial criteria [19], were obtained from the population-based register in the Netherlands for the cohort 2006–2015. This register was approved by the UMC Utrecht medical ethics review committee. To obtain the broadest possible cross section and avoid dependency in the data, only the most recent observation per individual was included in the study. The sample (n = 1556) was split randomly into a calibration set (S1) and a validation set (S2).

Amyotrophic lateral sclerosis functional rating scale-revised

The ALSFRS-R is a disease-specific 12-item instrument that measures the extent to which patients with ALS are capable of performing functional activities independently [3]. The questionnaire is structured on a 5-point scale ranging from 4 to 0, where 4 indicates no loss of function and 0 total loss of function. The ALSFRS-R was developed to comprise four scales, each measuring one domain affected by the disease.

Statistical analyses

Exploratory factor analyses (EFA) of ordered categorical data with orthogonal (Varimax) and oblique (Promax) rotations were performed on the raw data of S1. Confirmatory factor analyses (CFA) were first conducted on the data of S1 and subsequently cross-validated in S2. Given the ordered categorical response format of the ALSFRS-R, CFA should be performed with the weighted least square mean- and variance-adjusted (WLSMV) estimator. However, it is impossible to compare non-nested, i.e., three-factor and four-factor, models using the WLSMV estimator. Using a simulation study, Rhemtulla and colleagues demonstrated that for ordered categorical data with five or more response categories, a robust maximum likelihood estimator, such as the maximum likelihood mean- and variance-adjusted (MLMV) estimator, can be used to obtain acceptable estimates [20], thus facilitating direct comparison of models based on Bayesian Information Criterion (BIC). The different models of the ALSFRS-R were, therefore, examined with both estimators. Goodness-of-fit was evaluated using the χ 2 statistic of exact fit, comparative fit index (CFI), Tucker–Lewis index (TLI), and root mean square error of approximation (RMSEA). For acceptable fit, TLI and CFI should be >0.90, and RMSEA <0.08. Non-nested models were compared with BIC. Nested models were compared with a Δχ 2 test. CFA-based estimation of reliability is considered a more adequate method for calculating scale reliability than the traditionally used coefficient alpha [21]. Therefore, scale reliabilities are estimated using parameter estimates of the optimal CFA model. Data screening and descriptive statistical analyses were conducted in Rstudio [22]. To assess potential bias due to missing data, both complete case and multiple imputation analyses were performed. Multiple imputation, EFA, and CFA were performed in Mplus Version 7 [23].

Competing confirmatory factor analytic (CFA) models of the ALSFRS-R

The first set of models (1a–1d) to be evaluated expressed the hypothesis that ALSFRS-R items constitute four domains. The first model (1a) specified a measurement model with uncorrelated factors and the second (1b) a less constrained measurement model with correlated factors. Subsequent models were respecified based on modification indices (MIs), which provide the expected drop in χ 2 if a parameter is freely estimated, and theoretical knowledge. The second set of models (2a–2d) expressed the hypothesis that ALSFRS-R items constitute three domains. Again, the first model (2a) specified a measurement model with uncorrelated factors and the second (2b), a measurement model with correlated factors. Subsequent models were also respecified based on MIs and theoretical knowledge. The specification of cross-loading items was considered acceptable when an item comprised a combination of functions, while the specification of correlated errors was considered acceptable when respective items had similar content. Path diagrams of competing models are depicted in Fig. 1. Mplus inputs of both optimal measurement models (1d, 2d) are provided in Online Resources 1 and 2.
Fig. 1

Path models of measurement models of the ALSFRS-R. Lighter arrows indicate the parameters that were added to the previous models; 1 speech, 2 salivation, 3 swallowing, 4 handwriting, 5 cutting food and handling utensils, 6 dressing and hygiene, 7 turning in bed and adjusting bed clothes, 8 walking, 9 climbing stairs, 10 dyspnea, 11 orthopnea, 12 respiratory insufficiency, B bulbar function, F fine motor function, G gross motor function, M motor function, R respiratory function

Path models of measurement models of the ALSFRS-R. Lighter arrows indicate the parameters that were added to the previous models; 1 speech, 2 salivation, 3 swallowing, 4 handwriting, 5 cutting food and handling utensils, 6 dressing and hygiene, 7 turning in bed and adjusting bed clothes, 8 walking, 9 climbing stairs, 10 dyspnea, 11 orthopnea, 12 respiratory insufficiency, B bulbar function, F fine motor function, G gross motor function, M motor function, R respiratory function

Results

Sample characteristics

Table 1 presents the demographic and clinical characteristics of both the complete study sample (N = 1556) and the two samples that were obtained by a random split of the data (N S1 = 788, N S2 = 788). As shown in Table 1, the two samples were comparable.
Table 1

Demographic and clinical characteristics of patients

SampleS1S2
n 1556778778
Sex, n (%)
 Female637 (40.9)321(41.3)316 (40.6)
 Male919 (59.1)457 (58.7)462 (59.4)
Site of onset, n (%)
 Bulbar511 (32.8)249 (32.0)262 (33.7)
 Spinal1039 (66.8)528 (67.9)511 (65.7)
 Missing6 (0.4)1 (0.1)5 (0.6)
El Escorial diagnosis, n (%)
 Definite ALS288 (18.5)144 (18.5)144 (18.5)
 Probable ALS663 (42.6)316 (40.6)347 (44.6)
 Probable ALS lab supported277 (17.8)150 (19.2)127 (16.3)
 Possible ALS328 (21.1)168 (21.6)160 (20.6)
Age, mean (sd)64.1 (11.0)64.3 (11.2)63.9 (10.8)
Age at onset, mean (sd)62.0 (11.3)62.3 (11.5)61.6 (11.0)
ALSFRS-R, mean (sd)a 35.1 (8.9)34.9 (9.0)35.3 (8.7)

ALSFRS-R amyotrophic lateral sclerosis functional rating scale-revised, S1 calibration set, S2 validation set

aRaw total score

Demographic and clinical characteristics of patients ALSFRS-R amyotrophic lateral sclerosis functional rating scale-revised, S1 calibration set, S2 validation set aRaw total score

Exploratory factor analysis (EFA)

To explore the measurement model of the ALSFRS-R EFA for four- and three-factor solutions were performed. The EFA of the three-factor solution produced a poor model fit. Both orthogonal and oblique rotations of the three-factor solutions yielded uninterpretable patterns of factor loadings (χ 2 = 550.20, df = 33, p < 0.001, RMSEA = 0.14). The EFA of the four-factor solution gave a better model fit (χ 2 = 73.21, df = 24, p < 0.001, RMSEA = 0.05). Both orthogonal and oblique rotations revealed a pattern of factor loadings that could be interpreted as representing bulbar, fine motor, gross motor, and respiratory function. However, the item on dressing and hygiene loaded onto two factors with orthogonal rotation. Furthermore, the item on turning in bed and adjusting bed clothes loaded onto two factors with both orthogonal and oblique rotation. Factor loading patterns of both rotations are presented in Table 2.
Table 2

Factor loadings of exploratory factor analyses

IndicatorOrthogonalOblique
V1V2V3V4P1P2P3P4
Speech 0.88 0.120.130.10 0.92 0.03−0.060.02
Salivation 0.84 −0.010.140.02 0.88 −0.10−0.01−0.03
Swallowing 0.87 0.160.290.09 0.86 0.060.13−0.03
Writing0.02 0.86 0.100.25−0.08 0.95 0.00−0.06
Cutting food and handling utensils0.15 0.89 0.110.250.05 0.98 −0.02−0.07
Dressing and hygiene0.09 0.76 0.12 0.55 −0.01 0.70 −0.040.35
Turning in bed and adjusting bedclothes0.18 0.58 0.16 0.69 0.10 0.41 −0.01 0.59
Walking0.030.280.14 0.92 −0.05−0.05−0.03 1.02
Climbing stairs0.080.330.20 0.89 −0.010.020.03 0.95
Dyspnea0.150.03 0.81 0.05−0.02−0.06 0.89 −0.09
Orthopnea0.260.11 0.79 0.17−0.04−0.02 0.81 0.04
Respiratory insufficiency0.160.28 0.46 0.290.030.18 0.42 0.18

Bold type indicates factor loadings >0.40

P1–P4 promax rotated loadings, V1–V4 varimax rotated loadings

Factor loadings of exploratory factor analyses Bold type indicates factor loadings >0.40 P1–P4 promax rotated loadings, V1–V4 varimax rotated loadings

Testing competing confirmatory factor analytic (CFA) models of the ALSFRS-R

CFA were performed with WLSMV and MLMV estimators. The two analyses produced a similar pattern of results. Furthermore, potential bias due to missing data was assessed with multiple imputation analyses yielding similar results. These are provided in Online Resource 3. Table 3 shows fit indices of competing measurement models. Four models were tested in each set of models. In measurement models with a four-factor structure, model fit was poor in the initial model (1a), but improved in subsequent models after the specification of correlated factors and cross-loading items on dressing and hygiene and turning in bed and adjusting bed clothes in the optimal model (1d). In measurement models with a three-factor structure, model fit was poor in the initial model (2a), but improved in subsequent models after the specification of correlated factors and correlated errors between items on walking and climbing stairs and writing and cutting food and handling utensils in the optimal model (2d). For both sets of measurement models, all less constrained models had a significant improvement over more constrained models (p < 0.0001).
Table 3

Fit statistics for confirmatory factor analyses

EstimatorModel χ 2 df CFITLIRMSEABIC
S1S2S1S2S1S2S1S2S1S2S1S2
MLMV1a863.90781.8854540.760.730.700.730.140.132362023553
1b444.47400.0148480.880.850.840.850.100.102302223040
1c253.27220.3747470.940.950.910.930.080.072273822777
1d152.95134.4146460.970.970.950.960.060.052259422655
2a732.83701.1754540.800.800.750.760.130.132343523436
2b610.05600.2351510.830.830.780.780.120.122324023301
2c330.32312.8550500.900.920.890.890.090.082283022888
2d226.89230.1149490.930.950.930.930.070.072268022771
WLSMV1a6312.914671.7754540.730.760.670.710.390.34
1b733.29632.2748480.970.970.960.960.140.13
1c431.89345.6547470.980.990.980.980.100.09
1d233.00199.7546460.990.990.990.990.070.07
2a1312.38998.2254540.950.950.930.940.180.15
2b922.86860.7151510.960.960.950.950.150.15
2c531.94458.1550500.980.980.970.970.110.10
2d341.07325.9049490.990.990.980.980.090.09

BIC Bayesian information criterion, CFI comparative fit index, MLMV maximum likelihood means and variance, RMSEA root mean square error of approximation, S1 calibration set, S2 validation set, TLI Tucker–Lewis index, WLSMV weighted least squares means and variance

Fit statistics for confirmatory factor analyses BIC Bayesian information criterion, CFI comparative fit index, MLMV maximum likelihood means and variance, RMSEA root mean square error of approximation, S1 calibration set, S2 validation set, TLI Tucker–Lewis index, WLSMV weighted least squares means and variance A comparison of BIC values in Table 3 shows that the four-factor model with cross-loading items (1d) has a lower BIC value than the three-factor model with correlated errors (2d), indicating that the former model has a better fit to the data. Models tested in S1 were cross-validated in S2. Furthermore, Table 3 demonstrates that patterns in S2 were similar to patterns in S1. Table 4 shows fully standardized factor loadings from model 1d in S2. Inspection of the estimates reveals that there is quite some variation between factor loadings, indicating that certain items contribute more to their respective domain score than others. Furthermore, correlations between factors range from weak to modest, indicating that ALSFRS-R subscales do not constitute one overall severity score.
Table 4

Estimates of the optimal confirmatory factor analytic model

Domains, itemsReliability95% CIFactor loadings, correlations95% CI
Bulbar function0.870.85–0.89
 Speech0.890.87–0.92
 Salivation0.830.79–0.86
 Swallowing0.940.92–0.96
Fine motor function0.900.89–0.92
 Writing0.870.85–0.90
 Cutting food and handling utensils0.950.92–0.97
 Dressing and hygiene0.680.65–0.73
 Turning in bed and adjusting bedclothes 0.47 0.42–0.53
Gross motor function0.890.88–0.91
 Dressing and hygiene 0.38 0.33–0.43
 Turning in bed and adjusting bedclothes0.570.51–0.62
 Walking0.930.91–0.96
 Climbing stairs0.980.96–1.00
Respiratory function0.760.71–0.82
 Dyspnea0.770.71–0.83
 Orthopnea0.990.93–1.07
 Respiratory insufficiency0.760.67–0.85
Bulbar function
 Fine motor function0.230.16–0.31
 Gross motor function0.110.03–0.20
 Respiratory function0.430.35–0.52
Fine motor function
 Gross motor function0.530.47–0.59
 Respiratory function0.350.26–0.43
Gross motor function
 Respiratory function0.320.23–0.42

Estimates were obtained with the WLSMV estimator and standardized (STDYX); italic type indicates cross-loading items

Estimates of the optimal confirmatory factor analytic model Estimates were obtained with the WLSMV estimator and standardized (STDYX); italic type indicates cross-loading items

Reliabilities of the ALSFRS-R subscales

Reliabilities of ALSFRS-R subscales were estimated using CFA-based estimation in S2. Reliability coefficients with 95% confidence intervals are displayed in Table 4. Inspection of these coefficients shows that all subscales demonstrate acceptable to good internal consistency. The narrowness of these confidence intervals indicates that they can be regarded as providing accurate estimates of the internal consistency.

Discussion

The primary objective of the present study was to assess the factorial validity of the ALSFRS-R. Our main finding is that the measurement model with a four-factor structure and two cross-loading items provides the best fit to the data. This is in contrast to previous studies that adopted a measurement model with a three-factor structure [5, 15, 16, 24], or a simple four-factor structure, i.e., without cross-loading items [17]. Cross-loading items have been listed in tables of previous reports [2, 3, 7, 18], but it seems their significance was not sufficiently recognized. These cross-loadings are, however, consistent with what clinicians come across in the assessment of ALS: that the items on dressing and hygiene and turning in bed and adjusting bed clothes measure activities that comprise both kinds of motor functioning. Including cross-loading items in the measurement model would, therefore, reflect the clinical reality. The application of our measurement model is, therefore, an adequate approach to assess disease severity in patients with ALS in existing data. For the application of the ALSFRS-R in future studies, a revision of its item set is justified. Ideally, items that comprise more than one question are adapted or deleted from the item set during the development of measurement instruments. A revision of the ALSFRS-R item set could comprise items that are considered important indicators of disease severity by clinicians and patients. An example of a set of candidate items can be found in Wicks and colleagues [18], which was developed to measure disease severity in advanced stages of the disease. Furthermore, our analyses indicate that measurement models of the ALSFRS-R with correlated factors describe the data significantly better than their equivalent with uncorrelated factors. The correlations between factors do, however, range from weak to modest, corroborating previous reports by Franchignoni and colleagues that the hypothesis that the ALSFRS-R is unidimensional is untenable [15, 16]. Due to this multidimensionality, ALSFRS-R items cannot validly be summed to obtain a total score that represents disease severity. Consequently, ALSFRS-R items constitute domain scores which reflect a profile of disease severity. Moreover, the application of these domain scores may allow a distinction between different trajectories of disease progression [24]. Our revision of the measurement model of the ALSFRS-R may, therefore, allow for a more adequate assessment of disease severity and disease progression in epidemiological studies and clinical trials. With regard to reliability, our study supports the finding that all ALSFRS-R subscales demonstrated acceptable to good internal consistency. Strengths of the present study are the use of both a calibration set and a validation set and the use of modification indices to investigate the measurement model of the ALSFRS-R. A weakness is that we only used data of patients administered a Dutch version of the ALSFRS-R. The generalizability of our findings should, therefore, be investigated in a cross-cultural study. Furthermore, the present study examined the measurement model in the ALS population. Given the heterogeneity of the disease [25], results might be different in subgroups of the population. Future studies should, therefore, assess measurement invariance of the ALSFRS-R between clinical subgroups of patients with ALS. Our findings do complement earlier findings that ALSFRS-R items constitute a profile of domain scores, rather than a total score representing disease severity. Moreover, results of our study indicate that its measurement model should be revised to reflect the fact that the items on dressing and hygiene and turning in bed and adjusting bed clothes measure activities of daily living, which comprise both fine and gross motor functioning. Our findings may, therefore, allow for a more detailed analysis of disease severity and disease progression. Further studies on the measurement properties of the ALSFRS-R are necessary to expand the evidence on the appropriateness of its application. Below is the link to the electronic supplementary material. Online Resource 1. Mplus input for a confirmatory factor analysis of the ALSFRS-R using a measurement model with three-factor structure and correlated errors. Online Resource 2. Mplus input for a confirmatory factor analysis of the ALSFRS-R using a measurement model with four-factor structure and two cross-loading items. Online Resource 3. Fit statistics for confirmatory factor analyses after multiple imputation (DOCX 27 kb)
  22 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Cross-cultural adaptation and validation of als Functional Rating Scale-Revised in Portuguese language.

Authors:  Keyte Guedes; Cecília Pereira; Karina Pavan; Berenice Cataldo Oliveira Valério
Journal:  Arq Neuropsiquiatr       Date:  2010-02       Impact factor: 1.420

3.  Telephone follow-up for patients with amyotrophic lateral sclerosis.

Authors:  M Mannino; E Cellura; G Grimaldi; P Volanti; F Piccoli; V La Bella
Journal:  Eur J Neurol       Date:  2007-01       Impact factor: 6.089

4.  Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.

Authors:  Elizabeth D Bacci; Dorota Staniewska; Karin S Coyne; Stacey Boyer; Leigh Ann White; Neta Zach; Jesse M Cedarbaum
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-10-16       Impact factor: 4.092

5.  Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.

Authors:  J M Cedarbaum; N Stambler
Journal:  J Neurol Sci       Date:  1997-10       Impact factor: 3.181

6.  Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.

Authors:  Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Romana Rizzi; Vladimiro Pietrini; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Silvia De Pasqua; Eleni Georgoulopoulou; Antonio Fasano; Salvatore Ferro; Roberto D'Alessandro
Journal:  Neurol Sci       Date:  2015-07-24       Impact factor: 3.307

7.  Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial.

Authors:  Petra Kaufmann; Gilbero Levy; Jacquelina Montes; Richard Buchsbaum; Alexandra I Barsdorf; Vanessa Battista; Rachel Arbing; Paul H Gordon; Hiroshi Mitsumoto; Bruce Levin; John L P Thompson
Journal:  Amyotroph Lateral Scler       Date:  2007-02

8.  Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure.

Authors:  Susanne Abdulla; Stefan Vielhaber; Sonja Körner; Judith Machts; Hans-Jochen Heinze; Reinhard Dengler; Susanne Petri
Journal:  J Neurol       Date:  2013-06-05       Impact factor: 4.849

9.  Measuring function in advanced ALS: validation of ALSFRS-EX extension items.

Authors:  P Wicks; M P Massagli; C Wolf; J Heywood
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

10.  Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis.

Authors:  Franco Franchignoni; Gabriele Mora; Andrea Giordano; Paolo Volanti; Adriano Chiò
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-20       Impact factor: 10.154

View more
  11 in total

1.  Evaluation of ALSFRS-R Scale with Fuzzy Method in Amyotrophic Lateral Sclerosis.

Authors:  Gizem Gül Koç; Cansu Dağsuyu; Ali Kokangül; Filiz Koç
Journal:  Noro Psikiyatr Ars       Date:  2022-01-31       Impact factor: 1.339

2.  Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.

Authors:  Leigh E Colvin; Zachariah W Foster; Thor D Stein; Manisha Thakore-James; Mohammad Kian Salajegheh; Kendall Carr; Keith R Spencer; Nazifa Abdul Rauf; Latease Adams; James G Averill; Sean E Walker; Ian Robey; Victor E Alvarez; Bertrand R Huber; Ann C McKee; Neil W Kowall; Christopher B Brady
Journal:  Muscle Nerve       Date:  2022-06-04       Impact factor: 3.852

3.  Timing of Communication Device Introduction Defined by ALSFRS-R Score in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Ayumi Nobematsu; Kayoko Takahashi
Journal:  Prog Rehabil Med       Date:  2020-06-27

4.  Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.

Authors:  Maggie C Walter; Stephan Wenninger; Simone Thiele; Julia Stauber; Miriam Hiebeler; Eva Greckl; Kristina Stahl; Astrid Pechmann; Hanns Lochmüller; Janbernd Kirschner; Benedikt Schoser
Journal:  J Neuromuscul Dis       Date:  2019

5.  A machine-learning based objective measure for ALS disease severity.

Authors:  Fernando G Vieira; Subhashini Venugopalan; Alan S Premasiri; Maeve McNally; Aren Jansen; Kevin McCloskey; Michael P Brenner; Steven Perrin
Journal:  NPJ Digit Med       Date:  2022-04-08

6.  Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study.

Authors:  Mónica Povedano; Andrés Paipa; Miquel Barceló; Michael K Woodward; Sandra Ortega; Raúl Domínguez; Maria Esperança Aragonés; Raquel Horrillo; Montserrat Costa; Antonio Páez
Journal:  Neurol Sci       Date:  2021-11-18       Impact factor: 3.830

7.  Thickening fraction as a measure of ultrasonographic diaphragm dysfunction in amyotrophic lateral sclerosis.

Authors:  Lakshmi P Digala; Raghav Govindarajan
Journal:  Clin Neurophysiol Pract       Date:  2020-01-30

8.  Selective and Inverse U-Shaped Curve Alteration of the Retinal Nerve in Amyotrophic Lateral Sclerosis: A Potential Mirror of the Disease.

Authors:  Yixuan Zhang; Xiangyi Liu; Jiayu Fu; Yuanjin Zhang; Xue Yang; Shuo Zhang; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-01-06       Impact factor: 5.750

9.  The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.

Authors:  Eleonora Dalla Bella; Enrica Bersano; Giovanni Antonini; Giuseppe Borghero; Margherita Capasso; Claudia Caponnetto; Adriano Chiò; Massimo Corbo; Massimiliano Filosto; Fabio Giannini; Rossella Spataro; Christian Lunetta; Jessica Mandrioli; Sonia Messina; Maria Rosaria Monsurrò; Gabriele Mora; Nilo Riva; Romana Rizzi; Gabriele Siciliano; Vincenzo Silani; Isabella Simone; Gianni Sorarù; Valeria Tugnoli; Lorenzo Verriello; Paolo Volanti; Roberto Furlan; John M Nolan; Emmanuelle Abgueguen; Irene Tramacere; Giuseppe Lauria
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

10.  Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.

Authors:  Sabrina Paganoni; Eric A Macklin; Suzanne Hendrix; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret A Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry Heiman-Patterson; Carlayne E Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina N Fournier; Jonathan D Glass; Kristin M Johnson; Andrea Swenson; Namita A Goyal; Gary L Pattee; Patricia L Andres; Suma Babu; Marianne Chase; Derek Dagostino; Samuel P Dickson; Noel Ellison; Meghan Hall; Kent Hendrix; Gale Kittle; Michelle McGovern; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Eric Tustison; Prasha Vigneswaran; Jason Walker; Hong Yu; James Chan; Janet Wittes; Joshua Cohen; Justin Klee; Kent Leslie; Rudolph E Tanzi; Walter Gilbert; Patrick D Yeramian; David Schoenfeld; Merit E Cudkowicz
Journal:  N Engl J Med       Date:  2020-09-03       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.